The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics at all stages, from company formation to publics.

675+

Collective years of investing and operational experience

100

Portfolio companies

62

M&A and IPOs

34

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
Acquired by Sanofi in 2022
IPO in 2020 (NASDAQ:ARQT)
Acquired by Blueprint Medicines in 2021
IPO in 2019 (NASDAQ: PHAT)
IPO in 2020 (NASDAQ: TARS)
Acquired by Sanofi in 2021
Acquired by Pfizer in 2021

Life Sciences News

Frazier Life Sciences Team

Frazier Life Sciences Closes $987 Million Venture Fund to Invest in Companies Developing Novel Biopharmaceuticals

Amunix Pharmaceuticals

Sanofi completes acquisition of Amunix

Lengo Therapeutics

Blueprint Medicines Completes Acquisition of Lengo Therapeutics

Frazier Life Sciences Team

Frazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public Fund

View All News